Q4 2024 Biogaia AB Earnings Call Transcript
Key Points
- BioGaia AB (BIOGY) reported a 23% increase in sales for Q4 2024, with a 24% increase when excluding currency effects.
- The company's EBIT grew by 28% for the quarter, with a margin of 28%, indicating strong operational performance.
- Sales in the Americas increased by 32%, driven by significant growth in the US, Brazil, and Canada.
- The board proposed a total dividend of SEK6.90 per share, reflecting confidence in the company's financial health.
- BioGaia AB (BIOGY) launched several new products, including BioGaia Gastrus PURE ACTION, which is expected to enhance their market presence.
- Gross margin for the quarter decreased to 71% from 76% in the same quarter last year, indicating pressure on profitability.
- The pediatric segment experienced a significant inventory write-down in the USA, impacting gross margins negatively.
- Operating expenses grew by 7%, partly due to increased marketing and direct sales costs, which could pressure future profitability.
- Cash flow from operating activities decreased by 15% to SEK103 million, primarily due to higher tax payments.
- The company's cash reserves decreased to SEK1.22 billion from SEK1.54 billion in the same quarter last year, indicating a reduction in liquidity.
Welcome to Biogaia Q4 report for 2024.
(Operator Instructions)
Now I will hand the conference over to CEO, Theresa Agnew, and CFO, Alexander Kotsinas. Please go ahead.
Hi, this is Theresa Agnew, CEO of Biogaia. We're here to present our Q4 results.
As an overall, executive summary for the quarter, our sales were SEK365 million, which is growth of 23%, and excluding currency effects, that's growth of 24%. Sales in Europe, Middle East, Africa increased by 24%, in Asia Pacific by 10%, and in the Americas by 32% for the quarter.
Our EBIT was SEK103 million, which is growth of 28%, and our margin of 28% for the quarter. If you look at the total year, the total year for 2024, we had sales of approximately SEK1.4 billion, which is growth of 10%.
We had an EBIT margin of 30%, adjusted EBIT margin of 34%, which is without the MetaboGen impairment loss and if you look at the regions for the total of 2024, Europe, Middle East, Africa grew 3%, Asia Pacific grew
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
